Dr. Benson on Frontline Treatment Considerations in mCRC

November 1, 2019
Al B. Benson, MD
Al B. Benson, MD

Al B. Benson, MD, discusses key considerations in the frontline treatment of patients with metastatic colorectal cancer.

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses key considerations in the frontline treatment of patients with metastatic colorectal cancer (mCRC).

Understanding the broad picture of the patient is a key part of creating an optimal treatment course for the patient, explains Benson, especially as patient-specific characteristics can influence later-line therapies.

Notable characteristics includes sites of disease, patient performance status, and patient preference, explains Benson. Genomic characteristics such as microsatellite instability status and RAS, NRAS, BRAF, or in RAS wild-type tumors, HER2 mutations, is also important to know.

With a thorough patient profile, the optimal treatment strategies can be selected for the individual, concludes Benson.


x